KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Shares Outstanding (Weighted Average) (2018 - 2025)

Aurinia Pharmaceuticals (AUPH) has disclosed Shares Outstanding (Weighted Average) for 8 consecutive years, with $135.2 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Shares Outstanding (Weighted Average) fell 5.71% year-over-year to $135.2 million, compared with a TTM value of $135.2 million through Sep 2025, down 5.71%, and an annual FY2024 reading of $143.1 million, changed 0.12% over the prior year.
  • Shares Outstanding (Weighted Average) was $135.2 million for Q3 2025 at Aurinia Pharmaceuticals, down from $136.9 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $144.0 million in Q1 2024 and bottomed at $127.4 million in Q1 2021.
  • Average Shares Outstanding (Weighted Average) over 5 years is $138.8 million, with a median of $141.9 million recorded in 2022.
  • The sharpest move saw Shares Outstanding (Weighted Average) increased 13.72% in 2021, then decreased 5.71% in 2025.
  • Year by year, Shares Outstanding (Weighted Average) stood at $129.4 million in 2021, then rose by 9.7% to $141.9 million in 2022, then grew by 0.93% to $143.2 million in 2023, then fell by 0.12% to $143.1 million in 2024, then dropped by 5.52% to $135.2 million in 2025.
  • Business Quant data shows Shares Outstanding (Weighted Average) for AUPH at $135.2 million in Q3 2025, $136.9 million in Q2 2025, and $138.9 million in Q1 2025.